Author(s): Chen YB, Driscoll JP, McAfee SL, Spitzer TR, Rosenberg ES,
Abstract Share this page
Abstract Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.
This article was published in Clin Infect Dis
and referenced in Journal of Antivirals & Antiretrovirals